You are here

Trajenta

Trajenta Meets Primary Endpoint in Cardiovascular Trial

CP Wire

Thu, 07/19/18 - 09:47 am

Boehringer Ingelheim

Trajenta Meets Primary Endpoint in Cardiovascular Trial

Thu, 07/19/18 - 09:47 am

Boehringer Ingelheim

Diabetes Drug Shakeup: What You Need to Know About New FDA Warnings

Motley Fool

Tue, 04/19/16 - 09:50 am

Eli Lilly/ Boehringer Drug Under FDA Review

Yahoo/Zacks.com

Tue, 04/15/14 - 04:49 pm

Boehringer Ingelheim

type 2 diabetes

Lilly, Boehringer diabetes drug Trajenta receives European marketing approval

Yahoo/AP

Thu, 08/25/11 - 01:28 pm

Boehringer Ingelheim